


<p>Bissan Al-Lazikani Head of Data Science</p> <p>The Institute of Cancer Research, London, UK</p>		<p>Professor Bissan Al-Lazikani is Head of Data Science at the Institute of Cancer Research. There she leads the Big Data efforts to tackle key problems in Cancer drug discovery and Cancer therapy.</p> <p>Bissan led the development of integrative computational approaches to inform drug discovery that are now internationally adopted and provided to the community via the canSAR knowledgebase. She applies data science and machine learning approaches to the discovery of novel therapies and pharmacological and radiation to adapting and individualising therapy to patients.</p> <p>Bissan has a B.Sc (Hons) in Molecular Biology from University College London, an M.Sc in Computer Science from Imperial College and a PhD in Computational Biology from Cambridge University.</p> <p>Bissan has worked on drug discovery and personalised medicine both in academia and industry.</p>
<p>Gert Attard Professor of Urological Cancer Research</p> <p>University College London, UK</p>		<p>Prof Attard is a John Black Charitable Foundation Endowed Chair in Urological Cancer Research at University College London. He holds an advanced Cancer Research UK Clinician Scientist award and is Team Leader of the Treatment Resistance Group at the UCL Cancer Institute. He graduated with a degree in Medicine from the University of Malta in June 1999 and obtained a PhD in Medicine from the University of London (ICR) in 2010.</p> <p>His main research interest is dissecting treatment resistance, currently with a focus on plasma DNA analysis, in order to inform on the development of novel therapeutics and biomarkers for castration resistant prostate cancer (CRPC). He is an experienced clinical trialist in CRPC and a co-author of more than 130 peer-reviewed manuscripts, including several important papers on advanced prostate cancer.</p> <p>Prof Attard's many awards over the years include the ASCO Foundation Annual Merit Award in 2007, Prostate Cancer Foundation Young Investigator Award in 2008, the AACR-GlaxoSmithKline Outstanding Clinical Scholar Award in 2009, the Medical Research Society/Academy of Medical Sciences Sue McCarthy Prize in 2010 and the McElwain award in 2010. He received the Cancer Research UK Future Leader Award in 2017.</p> <p>Prof Attard sits on a number of advisory boards and is the GU associate editor of Annals of Oncology.</p>

Johann de Bono
Head of Clinical
Studies

The Institute of
Cancer
Research/Royal
Marsden Hospital,
London, UK



I am the Head of the Division of Clinical Studies at The ICR and the Director of the Royal Marsden Drug Development Unit, leading the NIHR Experimental Cancer Medicine Centre team and co-lead the NIHR Biomedical Research Centre. I am a key opinion leader in the development of novel cancer therapies and co-founded and now run The Royal Marsden Drug Development Unit, one of the world's largest such trials units for cancer patients. I also lead The London Movember Prostate Cancer Centre of Excellence and the Prostate Cancer Targeted Therapies team. I am a world leader in prostate cancer research, having changed the treatment of prostate cancer multiple times, through trials of The ICR-discovered drug [abiraterone](#), [cabazitaxel](#) and [enzalutamide](#). I also led on the identification of germline and somatic DNA repair defects in lethal prostate cancer, and co-led studies mapping its molecular landscape, also showing how circulating biomarkers can be used for managing this disease. My work has changed international guidelines on germline testing in men with advanced prostate cancer, and the first molecular stratification for this commonest of male cancers. My work has been recognized by multiple awards including The European Society for Medical Oncology (ESMO) Award, The American Association of Cancer Research (AACR) Team Science Award, a Royal Society of Chemistry Teamwork in Innovation Award and the 2018 AACR –Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research. I have served as the ESMO 2014 Scientific Programme Chair, the AACR 2015 and 2016 Clinical Program Co-Chair, the NCRI Annual Meeting 2016 and 2017 Deputy Chair and Chair, the Prostate AACR 2017 meeting Scientific Chair, and the ESMO Targeted Anticancer Therapy (TAT) Scientific Programme Chair.

Freddie Bray
Section Head,
Section of Cancer
Surveillance,
International Agency
for Research on
Cancer



Dr Bray is Section Head of the Cancer Surveillance Section at the International Agency for Research on Cancer (IARC), in Lyon, France. He has published over 350 peer-reviewed scientific reports, with his main areas of research revolving around the descriptive epidemiology of cancer globally. In support of the overwhelming need for high quality cancer surveillance systems given their current paucity and an ever-increasing cancer problem, Dr Bray leads the Global Initiative for Cancer Registration (<http://gicr.iarc.fr>), an international multi-partner programme designed to ensure a sustainable expansion of the coverage and quality of population-based cancer registries in LMIC through tailored, localized support and advocacy to individual countries. Dr Bray has a BSc (Hons) in Statistics from Aberdeen University, an MSc in Medical Statistics from University of Leicester and a PhD in Epidemiology from London School of Hygiene and Tropical Medicine.

Eva Compérat
Head of the
Department of
Pathology

Tenon Hospital,
Sorbonne
University, Paris,
France and
AKH Medical
University, Vienna,
Austria



Eva Compérat is Head of the Department of Pathology at the L'Assistance Publique-Hôpitaux de Paris, Hôpital Tenon, in Paris, France, consulting pathologist at the Comité de Cancerologie of the Association Française d'Urologie, and consulting pathologist specialising in muscle-invasive and non-muscle-invasive bladder cancer and penile carcinoma for the European Association of Urology (EAU). A member of several notable international societies in uropathology including the EAU, the International Society of Urological Pathology, and the Genitourinary Pathology Society, Professor Compérat serves (or has served) on the editorial boards of journals including *World Journal of Urology*, *Pathology*, and *European Urology Oncology*, and is recognized as co-author of *WHO Tumours of the Urinary System and Male Genital Organs (4th ed.)*. Professor Compérat is equally dedicated to educational efforts in her specialised field (she has held a teaching position at the Université Pierre et Marie Curie in Paris since 2002), and is a frequent contributor to educational exchanges of the International Academy of Pathology.

Ros Eeles
Professor of
Oncogenetics and
Honorary
Consultant in
Clinical Oncology
and Cancer
Genetics

The Institute of
Cancer
Research/Royal
Marsden Hospital,
London, UK



Professor Ros Eeles is an international expert in the field of cancer genetics. She is an oncologist specialising in the treatment of prostate and bladder cancer. She runs a research programme at The Institute of Cancer Research and Royal Marsden on genetic predisposition to prostate cancer and management of individuals with higher risk cancer predisposition gene mutations. She runs several studies in targeted screening in higher risk individuals involving over 65 centres in 20 countries.

Omolara Fatiregun
Lecturer and Clinical
and Radiation
Oncology
Consultant

Lagos State
University Teaching
Hospital, Lagos,
Nigeria



Dr. Omolara Fatiregun is a lecturer at the College of Medicine, Lagos State University. She is also a Honorary Consultant, Clinical and Radiation Oncologist at the Oncology Unit/Cancer Screening and Treatment Unit, Department of Radiology, Lagos State University Teaching Hospital, Ikeja, Lagos. She is a fellow of the West Africa College of Surgeons, Faculty of Radiology (Clinical & Radiation Oncology) as well as an Associate fellow of the National Postgraduate Medical College of Nigeria. She has received fellowship awards like the UICC/ICRETT Cancer award to the University of Chicago, Illinois and the IAEA Fellowship for strengthening Radiotherapy services in Africa at Stellenbosch University & Tygerberg Hospital, Cape Town, South Africa. She also received the Commonwealth Scholarship award to the University of Birmingham, Birmingham, United Kingdom in 2017.

- She is a currently a research committee member for the African Organization for Research & Training in Cancer (AORTIC)
- Site PI, Trans-Atlantic Prostate cancer consortium (CapTc)
- Site Co-PI, Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women with Breast Cancer (ARRETTA) trial.
- Member, Association of Radiation & Clinical Oncologists of Nigeria (ARCON)
- Member, American Society of Clinical Oncologists (ASCO).

Felix Feng
Professor of
Radiation Oncology,
Urology and
Medicine

University of
California, San
Francisco, USA



Felix Feng, MD, received his undergraduate training from Stanford University, where he earned a degree in Biological Sciences and received a President's Award for Academic Excellence. He then received his MD from Washington University in St. Louis, where he received numerous awards for his research and academic achievements. He then completed both a postdoctoral research fellowship and his residency in radiation oncology at the University of Michigan, and subsequently joined the faculty there. In addition to being the Director of the Division of Translational Genomics, Dr. Feng also co-lead the multidisciplinary clinic for prostate cancer patients and served as Director of the Genitourinary Cancer Program within the Department of Radiation Oncology at the University of Michigan. In 2016, Dr. Feng was recruited to join the faculty at UCSF, where he currently is the George and Judy Marcus Distinguished Professor of Radiation Oncology, Urology, and Medicine, Vice Chair for Translational Research for the Department of Radiation Oncology, and a Program Leader for the Prostate Cancer Program at the Helen Diller Family Comprehensive Cancer Center. Dr. Feng also is Executive Director of the Benioff Initiative for Prostate Cancer Research, a university-wide initiative focused on translational research for prostate cancer, and chairs the Genitourinary Cancer Committee for NRG Oncology, an international clinical trials group.

Silke Gillessen
Head of Department
of Medical
Oncology/Medical
and Scientific
Director

Oncology Institute of
Southern
Switzerland (IOSI)



Professor Silke Gillessen is a Medical Oncologist with focus on genitourinary cancers.
Prof Gillessen was appointed from January 2020 as Head of the Department of Medical Oncology, full professor at the USI and Director of the IOSI in Lugano and Bellinzona.
Prof Gillessen completed her training in Basel, St. Gallen, and the Dana Farber Cancer Institute, Boston. After returning to Switzerland, she built up the medical oncology unit for genitourinary cancer in Cantonal Hospital, St Gallen and lead the Clinical Research Department. From 2018, Prof Gillessen has been Genitourinary Cancer Systemic Therapy Research Chair at the University of Manchester and Honorary Consultant at The Christie Hospital. Currently she still holds an Honorary Professorship at the University of Manchester. She is a member of the Scientific Committee of the ESMO guidelines and a panellist of the EAU guidelines for prostate cancer.

		<p>She served for two terms as president of the SAKK GU group. She chaired the EORTC Genitourinary Cancers Group, and has founded the Advanced Prostate Cancer Consensus Conference (APCCC).</p>
<p>Susan Halabi Professor of Biostatistics and Bioinformatics</p> <p>Duke Cancer Institute, Durham, North Carolina, USA</p>		<p>Susan Halabi is a co-Chief, Division of Biostatistics, and Professor of Biostatistics and Bioinformatics, Department of Biostatistics and Bioinformatics, Duke University Medical Center. Dr. Halabi has been designing and analyzing clinical trials for over 23 years and has provided statistical services, in addition to teaching and consulting, to both the Duke University Medical community and at the national level. She has published over 200 articles and chapters in medical and statistical journals. She recently co-edited a book on <i>Oncology Clinical Trials</i>. Dr. Halabi is currently the President of the Society for Clinical Trials.</p> <p>She has served as scientific and an <i>ad-hoc</i> reviewer on several study sections, special panels at the NIH, the Department of Defense and the Food and Drug Administration. She is an Associate Editor for <i>Clinical Trials</i>, <i>Statistics in Medicine</i> and <i>Diagnostic and Prognostic Research</i>. In addition, she serves as a statistician on several Data Safety and Monitoring Committees in cardiovascular and cancer trials. Dr. Halabi is a member of the Oncology Drugs Advisory Committee for the Food and Drug Administration. Dr. Halabi is a fellow of the Society of Clinical Trials, fellow of the American Statistical Association and fellow of the American Society of Clinical Oncology.</p>
<p>Daniel Herchenhorn Scientific Coordinator, Oncologia D' Or Group</p> <p>LACOG – Latin America Cooperative Group, Rio de Janeiro, Brazil</p>		<p>Dr Daniel Herchenhorn is the youngest physician and the first medical oncologist to be elected as a full member of the Rio de Janeiro Academy of Medicine. He worked for more than 20 years as an oncologist and clinical investigator at the Brazilian National Cancer Institute (INCA), where he was the head of the Department of Clinical Oncology and responsible for the incorporation of targeted therapy agents and molecular testing at the institution, as well as an ad-hoc advisor for ANVISA (Brazilian National Sanitary Agency). During that period he designed and conducted the first phase 1/2 studies at INCA leading to the integration of clinical and translational departments, when he received his PhD in Clinical Oncology. His focus on prostate cancer started when he worked as a PI at the TAX327 study, followed by several other phase 3 trials. Dr Herchenhorn was the co-founder of the Uro-Oncology branch of the Latin America Cooperative Oncology Group (LACOG), where he stays as one</p>

		<p>of its coordinators participating in several Latin-America uro-oncology guidelines. He received several research awards as the Global Young Investigator and Latin-America Research Award.</p> <p>Dr Herchenhorn is the Scientific Director and the Fellowship Coordinator at Grupo de Oncologia D`Or, and an investigator at IDOR (Institute D`Or de Ensino e Pesquisa) the biggest private hospital and oncology group in Latin-America.</p>
<p>Michael Hofman Nuclear Medicine physician and physician-scientist</p> <p>Peter MacCallum Cancer Centre, Melbourne, Australia</p>		<p>Professor Michael Hofman is a nuclear medicine physician and physician-scientist at the Peter MacCallum Cancer Centre in Melbourne. He previously completed a research fellowship at Guy's & St Thomas' in London. He has broad research interest in radiopharmaceuticals for imaging and therapy (theranostics) in oncology. This includes neuroendocrine tumours and haematologic applications and more recently has focussed on improving outcomes for men with prostate cancer.</p> <p>Dr Hofman has a strong track record leading Phase I, II and III clinical trials ranging from first-in-human evaluation of novel radiopharmaceuticals to conducting large mutli-centre randomised clinical trials. In the latter, through his involvement on the scientific committee of the The Australasian Radiopharmaceutical Trials Network (ArtNet), he has established a network of more than 10 centres around Australia with multi-disciplinary expertise culminated in research presented at leading conferences (ESMO, ASCO, EAU) and published in high impact journal such as The Lancet. He has active grants as chief investigator totalling more than \$15 million dollars including the Prostate Cancer Foundation (PCF), Movember, Medical Research Future Fund (MRFF), Prostate Cancer Foundation of Australia (PCFA) and the U.S. Department of Defence.</p>

Mohamed Jalloh
Consultant Urologist

Hospital General De
Grand Yoff, Dakar,
Senegal



Dr Mohamed Jalloh is a urologist trained in Senegal (West Africa) and working as a consultant urologist at the Hopital General de Grand Yoff, Dakar and Assistant Professor of Urology at the University Cheikh Anta Diop de Dakar. He has expertise in the treatment of urological cancers and research on prostate cancer (PCa) in men of African descent. He contributed to running an NIH funded research project on prostate cancer under Dr Serigne Gueye co-PI in collaboration with Dr Timothy Rebbeck co-PI from University of Pennsylvania. Such research focused on a better understanding of clinical and molecular epidemiology of PCa in Senegalese men with an emphasis on developing research infrastructure.

This research was further enlarged in a consortium, the Men of African Descent Carcinoma of the Prostate (MADCaP).

In 2012 he completed the Summer curriculum on “Principles and Practice of Cancer Prevention and Control Course” July 9th – August 3rd, 2012 and “Molecular Prevention Course” August 6th – 10th, 2012, NCI, Bethesda US.

In 2013, he completed a UCSF/SIU Post-Doctoral research training in Urologic Oncology at the University of California San Francisco and published peer reviewed papers on prostate cancer.

In 2015, he completed a Masters of Public Health: Management and Control of health programme at the University Alioune Diop of Bambey, Senegal.

He contributed in developing standardized and culturally tailored data elements and measures for PCa research in black men using the NCI–Grid-Enable Measures (GEM) platform. The aim was to facilitate data harmonization and data sharing for multiethnic studies of Black men globally and these measures can be used by other researchers in this area.

Dr Jalloh is currently investigator in a NIH/NCI grant funded to MADCaP to study the genetics of PCa in Sub Saharan Africa (U01CA184374 – Dr Timothy Rebbeck PI in the period 2019-2024).

Dr Jalloh is currently Secretary General of the Pan African Urological Surgeons’ Association (PAUSA) and serves as associate editor to the African Journal of Urology (PAUSA Journal). He is also Treasurer of the Senegalese Association of Urology. He was also member of the Research Committee of the African Organization for Research and Training in Cancer (AORTIC) in the period 2017-2019.

Nick James

Professor of Prostate and Bladder Cancer Research

The Institute of Cancer Research, London, UK



Professor James is Professor of Prostate and Bladder Cancer Research at the Institute of Cancer Research and an Honorary Consultant at the Royal Marsden Hospital in London. He was previously Professor of Clinical Oncology in Birmingham up until 2019.

Prof. James is chief investigator on the STAMPEDE trial, which has been used to evaluate, to date, 10 different therapies for advanced prostate cancer in more than 11,000 men. Results from STAMPEDE with docetaxel and abiraterone and prostate radiotherapy have shown that big survival gains can be made by using existing treatments in novel settings.

In the bladder cancer field Prof James has led a series of trials of chemoradiotherapy that demonstrated that low dose synchronous chemotherapy reduced invasive bladder cancer relapse rates by 43%, published in the New England Journal of Medicine.

Stacy Loeb

Professor of Urology and Population Health

New York University and Manhattan Veterans Affairs, New York, USA



Dr. Stacy Loeb is a Professor of Urology and Population Health at the New York University School of Medicine and the Manhattan Veterans Affairs Medical Center. Dr. Loeb is an expert in prostate cancer with more than 300 peer-reviewed published articles and 10 book chapters. She currently has grants from the Prostate Cancer Foundation and Department of Defense for her research on prostate cancer. Dr. Loeb also hosts the Men's Health Show on Sirius XM US/Canada satellite radio and serves on the American Urological Association Public Media Committee.

Brandon Mahal
Assistant Professor
of Radiation
Oncology and
Assistant Director of
Community
Outreach and
Engagement

University of Miami,
Miami, USA



Dr. Mahal is Assistant Professor of Radiation Oncology and Assistant Director of Community Outreach and Engagement at the Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine. He obtained his Doctor of Medicine (M.D.) with Honors at Harvard Medical School. Dr. Mahal developed an early focused interest in prostate and genitourinary cancers during medical school under the mentorship of Dr. Anthony D’Amico and Dr. Paul Nguyen, both world renowned prostate cancer experts. Dr. Mahal then completed an internal medicine internship at Harvard Medical School’s Brigham and Women’s Hospital, before completing residency in Radiation Oncology at the Harvard Radiation Oncology Program (Massachusetts General Hospital, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston Children’s Hospital). During residency at Harvard, Dr. Mahal trained in the Holman Research Pathway which is “designed for exceptional trainees with both strong clinical abilities and a background in research.” He was recruited to Miami in 2020 as Assistant Director of Community Outreach and Engagement. Dr. Mahal’s clinical interests are in prostate and genitourinary cancers and his research focus is in cancer health disparities, translational epidemiology, genomics, and precision medicine.

Caroline Moore
Professor of
Urology, UCL
Division of Surgery
and Interventional
Medicine

University College
London, UK



Caroline Moore is the first woman in the UK to become a Professor of Urology. She is passionate about improving the diagnostic and treatment pathway for men with prostate cancer, using the latest in imaging technology, decision support and outcomes measurement. She has a particular interest in the use of MRI in the diagnosis and active surveillance of prostate cancer, and had led international consensus and group work in this area, including the START consensus on reporting studies of MRI-guided biopsy, the PRECISE consensus on reporting MRI in men on active surveillance for prostate cancer and the PRECISION study demonstrating the superiority of an MRI-targeted prostate cancer diagnosis pathway. She also studies the impact of prostate cancer diagnosis and treatment on patient reported outcome measures. She leads national and international work in this area, supported by major funders including Movember, Prostate Cancer UK, the National Institute for Health Research and the Medical Research Council. She is the Head of Urology, University College London, and the Integrated Academic Training lead for Urology at University College London.

Alicia Morgans
Associate Professor
of Medicine


Northwestern
Medicine, Chicago,
USA



Alicia Morgans, MD, MPH is an Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. She specializes in investigating complications of systemic therapy for prostate cancer survivors, including the study of skeletal, cardiovascular, diabetic, and cognitive complications of prostate cancer survivorship. She also studies the way patients and their care teams make treatment decision making for metastatic prostate cancer. She has been awarded several Prostate Cancer Foundation grants to investigate the cognitive effects and quality of life effects of hormonal treatments in advanced prostate cancer, and a Department of Defense grant to assess treatment decision making. She serves on the advanced and localized guidelines committees of the American Urologic Association, and is a member of the cardio-oncology committee of American Heart Association. She also acts as the Principal Investigator for multiple therapeutic and non-interventional prostate cancer and bladder cancer clinical trials at Northwestern University.


Michael Morris
Medical Oncologist

Memorial Sloan
Kettering Cancer
Centre, New York,
USA



Dr. Morris is a prostate cancer specialist, clinical investigator, professor, and the Section Head of Prostate Cancer of the Genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center. He earned his medical degree from the Mount Sinai School of Medicine in New York, and performed his internship and residency in Internal Medicine at Columbia Presbyterian Medical Center. He then completed his medical oncology fellowship at Memorial Sloan-Kettering Cancer Center.

Dr. Morris has led numerous clinical trials, but he has a particular research focus on targeted therapy for prostate cancer, especially those that bridge the fields of Medical Oncology and Nuclear Medicine. In the field of therapeutics, he has focused on bone and tumor directed radioisotope therapy. In the field of diagnostics, he has a keen research interest in developing novel imaging technologies for metastatic prostate cancer and in developing novel imaging biomarkers, including novel prostate-specific imaging technologies such as FDHT PET and PSMA-directed PET imaging. He has been a co-developer of the Prostate Cancer Working Group 2 and 3 Consensus Criteria for prostate cancer clinical trial design.

		<p>In addition, he is the Medical Director of the Prostate Cancer Clinical Consortium and chairs the GU Committee of the Alliance for Oncology Trials in Oncology, an NCI-funded cooperative group for the conduct of cancer clinical trials.</p>
<p>Declan Murphy Director of Genitourinary Oncology, Director of Robotic Surgery and Consultant Urological Surgeon</p> <p>Peter MacCallum Cancer Centre, Melbourne, Australia</p>		<p>Professor Declan Murphy is Consultant Urologist and Director of Genito-Urinary (GU) Oncology at Peter MacCallum Cancer Centre, Melbourne, and Professorial Fellow at the University of Melbourne. He is a founding Director of Cancer Specialists.</p> <p>Declan is an internationally-recognised key opinion leader in GU Oncology, prostate cancer in particular, and has published hundreds of peer-reviewed papers. He has been Chief Investigator on competitive GU oncology grants worth many millions of dollars and leads an active team of clinical researchers at Peter Mac. He holds senior editorial positions at the BJUI, European Urology, Nature Reviews Urology, and Prostate Cancer & Prostatic Diseases, and is on the board of reviewers for many other journals.</p>
<p>Vedang Murthy, MD DNB, DipEPP Professor of Radiation Oncology</p> <p>Tata Memorial Centre, Mumbai, India</p>		<p>Vedang Murthy is a Professor and Radiation Oncologist at Tata Memorial Hospital, Mumbai, a premier oncology centre in Asia. Dr Murthy's area of expertise is in Urological Cancer. He has special interest in high precision radiotherapy procedures such as Image Guided Radiotherapy and Adaptive Radiotherapy. After completing his MD in Mumbai, Dr Murthy worked at The Royal Marsden NHS Foundation Hospital, London for a period of 4 years in the Academic Radiotherapy Unit. He also undertook a Diploma in Epidemiology and Biostatistics from the London School of Health and Tropical Medicine. He has over 100 publications in peer reviewed international journals. Dr Murthy is currently running several investigator initiated clinical trials including randomised controlled trials in prostate and bladder cancer and is a part of international co-operative groups in GU Oncology. The main areas of interest within GU oncology are high risk prostate cancer, SBRT for prostate and kidney cancer, oligometastatic prostate cancer, bladder preservation and adjuvant radiotherapy in bladder cancer.</p>

James N'Dow
Professor of
Urological Surgery

University of
Aberdeen, UK



Professor N'Dow gained his medical degree in the University of Aberdeen, where he is now Professor of Urological Surgery and Director of the Academic Urology Unit. He is appointed to the first Chair of Urological Surgery in Aberdeen's 525 year history as a medical school. Professor N'Dow has a General Urological Surgical practice in the University of Aberdeen Teaching Hospitals/NHS Grampian, sub-specialising in penile and urethral reconstructive surgery.

He is Chairman of the Clinical Practice Guidelines Office Board of a large global urological surgery society (European Association of Urology, EAU; with over 19,000 active Urological Surgeon members). Under his leadership, the EAU Guidelines have become the most comprehensive, trusted and up-to-date urological surgical practice guidelines globally; they are now endorsed by 74 national societies including all 27 EU member states, UK, China, India, and Australia, among others.

His research interests are in evidence synthesis and evidence based practice, implementation science, large observational studies and multicentre randomised clinical trials with a competitive research grant income of over USD\$ 40 million. He is coordinator of PIONEER, a European Commission IMI funded Prostate cancer big data for better outcomes project involving 34 partners <https://prostate-pioneer.eu>. He has a strong global health track record including Founder and Chairman of Horizons <http://horizonstrustuk.org/>. Professor N'Dow is Co-Founder and Managing Director of the Urological CANcer Scottish charity (UCAN; <https://www.ucanaberdeen.com/>). UCAN has raised over USD\$ 10 million so far and funded the opening of the first Urological Cancer Care Centre in Scotland, formally launched by the Health Minister in 2008. He has contributed to the UK National Institute of Clinical Excellence (NICE Guidelines), UK Urology Specialty Advisory Committee, and was Trustee for British Journal of Urology International for 5 years.

Paul L Nguyen
Professor of
Radiation Oncology

Harvard University,
Boston, USA



Dr. Paul Nguyen is an expert in prostate cancer clinical care and research with a focus on optimizing systemic therapy for high risk localized disease. He has published over 350 original research articles and has national leadership as the vice-chair of the ARS/ACR Appropriateness Criteria Committee for Prostate Cancer and Chair of the Program Committee for the 2019 ASTRO/SUO/ASCO Genitourinary Cancers Symposium. He is the Principal Investigator of the multi-center randomized FORMULA-509 trial, co-chair of the international randomized ENZARAD trial, and PI of the new NRG Oncology PREDICT-RT trial for high risk prostate cancer. He serves as the Dana-Farber/Brigham and Women's Cancer Center Genitourinary Clinical Center Director for Radiation Oncology, Vice-Chair for Clinical Research in the Department of Radiation Oncology, and Professor at Harvard Medical School. He received his AB from Harvard College, MD from Harvard Medical School, and completed his residency at the Harvard Radiation Oncology Program where he served as chief resident.

Anwar Padhani
Head of Imaging
Research

Mount Vernon
Cancer Centre,
London, UK



Prof. Anwar Padhani is an internationally recognized Oncological MRI radiologist at Mount Vernon Cancer Centre, London, UK. He is Professor of Cancer Imaging at the Institute of Cancer Research, London. He is on the executive board and trustee of the International Cancer Imaging Society (ICIS). He is also co-chair of the International Prostate PI-RADS committee. He has been instrumental in introducing multiparametric prostate MRI into clinical practice in the UK, contributing to UK guideline development, quality assurance programs and training. He has contributed to international guidelines development including the ESUR/ACR prostate PI-RADS committee, the St.Gallen advanced prostate cancer consensus committee and the American Society of Clinical Oncology (ASCO) advanced prostate cancer guidelines. He led efforts to standardize the use of whole-body MRI for metastasis response assessments (MET-RADS; 2017) and for myeloma (MY-RADS 2019) and WB-MRI screening.

He is a recognized cancer imaging expert looking after patients on a weekly basis. Prof. Padhani has a passion for teaching and has published chapters in 33 textbooks, 100 educational and scientific journal reviews in peer reviewed journals and published 160 full scientific articles in peer reviewed journals, with over 36,000 publications reads and over 20,000 citations. Prof. Padhani has

		<p>delivered over 400 lectures at scientific and educational meetings including several plenary talks. To his credit, he been awarded several education awards including outstanding teacher from the ISMRM, and honoured RSNA educator awards. He is the recipient of the International Cancer Imaging Society 2017 Gold medal.</p>
<p>Mark Sculpher Professor of Health Economics</p> <p>University of York, UK</p>		<p>Mark Sculpher is Professor of Health Economics and is Team Leader of the Programme on Economic Evaluation and Health Technology Assessment. He is also Co-Director of the Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU). He has been based at York University since 1997.</p> <p>Between 1988 and 1997, he worked at the Health Economics Research Group at Brunel University; during 1998 he was a visitor in the Department of Clinical Epidemiology and Biostatistics at McMaster University in Canada. Mark has worked on economic evaluations of a range of technologies including heart disease and various cancers. He has also contributed to methods in the field, in particular relating to decision analytic modelling and handling uncertainty. He has over 280 peer-reviewed publications and is a co-author of two major text books in the area: <i>Methods for the economic evaluation of health care programmes</i> (OUP, 2015 with Drummond, Claxton, Torrance, and Stoddart) and <i>Decision modelling for health economic evaluation</i> (OUP, 2006 with Briggs and Claxton). He was also a member of the Second Panel on Cost-Effectiveness in Health and Medicine.</p> <p>Mark was a member of the National Institute for Health and Care Excellence (NICE) Technology Appraisal Committee (2004-8), the NICE Public Health Interventions Advisory Committee (2006-9) and the NICE Diagnostics Advisory Committee (2010-20). He chaired NICE's 2004 Task Group on methods guidance for economic evaluation and was a member of the Methods Working Party for the 2008 update of this guidance. He was a member of the Commissioning Board for the UK NHS Health Technology Assessment Programme (2007-10), the UK National Institute for Health Research (NIHR)/Medical Research Council (MRC) Methodology Research Panel (2008-11) and the MRC-NIHR Methodology Research Advisory Group (2016-20). He was a member of the NIHR Policy Research Programme's Commissioning Panel (2011-14). Mark is a NIHR Senior Investigator (Emeritus) and is a former</p>

		<p>President of the International Society of Pharmacoeconomics and Outcomes Research.</p> <p>Recent national and international advisory roles include the Singapore Agency for Care Effectiveness International Advisory Panel (2017-18); UK Health Select Committee Availability of Orkambi on the NHS inquiry (2018-19); Portuguese National Authority of Medicines and Health Products (2018-20).</p>
<p>Howard Soule Executive Vice President and Chief Science Officer</p> <p>Prostate Cancer Foundation, Santa Monica, USA</p>		<p>Howard R. Soule, PhD, is the Executive Vice President and Chief Science Officer of the Prostate Cancer Foundation since 1997. He coordinates global academic, government and biopharmaceutical sector research activities for the Foundation and is responsible for the implementation of the Prostate Cancer Foundation global research funding strategies.</p> <p>Dr. Soule received a PhD from Baylor College of Medicine in Virology and Epidemiology and was a Post-Doctoral Fellow in Immunology and Vascular Biology at the Scripps Research Institute.</p>
<p>Matt Sydes Professor of Clinical Trials and Methodology</p> <p>University College London, UK</p>		<p>Matt is responsible for leading the unit's Trial Conduct Methodology activities where he has a particular interest in improving clinical trial conduct, particularly around: the use of routinely-collected electronic health records (EHR) to support and run trials with Health Data Research UK; running trials with a view to regulatory use and submission; proportionate and efficient trial monitoring; adaptive and efficient designs for late-phase trials, including in uncommon conditions; clinical trial data sharing; communication of trial findings; function of trial oversight committees. His first involvement in methodology was the DAMOCLES project which set standards for (independent) Data Monitoring Committees and led to the widespread use of charters for trial committees. He is part of the faculty for UCL's regular 1-day course on Data Monitoring Committees in practice and has served as a member of IDMCs and TSCs for around 50 trials, often as chair, attending around 200 meetings. Matt teaches on the UCL Institute of Clinical Trials and Methodology's MSc in Clinical Trials and is currently supervising a 5 PhD students in areas of methodological priority.</p>

		<p>Matt has served as lead statistician for STAMPEDE, a multi-arm multi-stage platform protocol in prostate cancer, a clinical trial which has delivered practice-changing results three times. The efficient RADICALS trial for post-operative treatment in earlier prostate cancer will soon report results. The trans-Atlantic EURAMOS-1 trial in osteosarcoma, a rare cancer, was the largest RCT conducted in this setting, thanks to an extensive international collaboration and has defined the standard-of-care. Matt commonly advises on trial design and conduct of external trials.</p>
<p>Ian Tannock Professor of Medicine and Medical Biophysics</p> <p>The Princess Margaret Hospital, University Health Network, Toronto, Canada</p>		<p>Dr. Tannock is Emeritus Professor of Medicine and Medical Biophysics at Princess Margaret Cancer Centre and University of Toronto. He obtained his PhD from the Institute of Cancer Research, London University, England and his MD at University of Pennsylvania, Philadelphia, USA. His clinical expertise is in GU and breast cancer. His research investigated methods related to cancer clinical trials, and he chaired trials for men with metastatic prostate cancer that led to licensing of drugs that are used worldwide for this disease. Dr. Tannock is an editor of the Basic Science of Oncology textbook, now in its 5th edition, that is used by trainees in all branches of oncology.</p> <p>Dr. Tannock was a member of the Board of Directors of ASCO from 2001-2004. He chaired (2018-2020) the ASCO working group that organizes International Clinical Trials Workshops, and has taught extensively in low and middle-income countries. He received the alumnus award from M.D. Anderson Hospital, Houston, USA (1989), the Warwick Prize from the National Cancer Institute of Canada (2003), an honorary degree (DSc) from London University, UK (2009), the ESMO award (2012), the first non-European to receive this award, and the ASCO Allen Lichter award for leadership and innovation (2019). He chaired the EORTC scientific audit committee between 2009 and 2016 and was then a member of the EORTC Board. Dr. Tannock was appointed to the Order of Canada in December 2013.</p>

Derya Tilki
Professor of Urology

Martini-Klinik,
Hamburg, Germany



Derya Tilki is an attending urologist at the Martini-Klinik Prostate Cancer Center Hamburg. She completed her residency training at the Department of Urology of the Ludwig-Maximilians-University, Munich. She subsequently completed a fellowship in Urologic Oncology at UC Davis in Sacramento. After completion, she joined the faculty at the Martini-Klinik Prostate Cancer Center. Her primary research focus is uro-oncology, with particular areas of interest including prostate cancer and outcomes research.

Nina Tunariu
Consultant
Radiology, Imaging
in Drug
Development

Royal Marsden
Hospital & The
Institute of Cancer
Research, London,
UK



Dr. Nina Tunariu works as a Consultant Radiologist at Royal Marsden Hospital, UK as the dedicated Radiologist for the Prostate Cancer Targeted Therapy and Drug Development Units. Dr. Tunariu's academic work is focused on the development of Whole Body MRI (WBMRI) as a research and clinical tool in oncological imaging.

Dr. Nina Tunariu qualified from the University of Medicine "Iuliu Hatieganu" in Romania (1997), completed general medical training at Imperial NHS Trust, Papworth NHS Hospital and Royal London Hospital and her Clinical Radiology training at Imperial College NHS Trust. In October 2008, Dr. Tunariu joined Institute of Cancer Research and Royal Marsden Hospital to undertake an Oncological Imaging Fellowship; in 2014 she has been awarded an MDRes for the thesis entitled "Standardisation of Data Analysis Methods for Multiparametric MRI in phase I clinical trials" by University of London.

Dr Tunariu's clinical and research interests include the integrated application of whole body multiparametric, multimodality imaging for response assessment in metastatic bone disease and for evaluation of tumour heterogeneity in prostate cancer patients.

Paul Villanti
Executive Director,
Programs

Movember,
Melbourne,
Australia



Paul oversees Movember program investments in prostate cancer, testicular cancer and mental health initiatives globally. He serves as a Director on the Board of Prostate Cancer Foundation (USA). Over the past 20 years Paul has successfully led and built organisations across the health, infrastructure, technology, and telecommunications sectors. He has a particular interest in leveraging Movember's role as a global funder to accelerate improved health outcomes through national and global collaboration.

Li-Ping Xie
Chairman,
Department of
Urology

First Affiliated
Hospital, Zhejiang
University School of
Medicine,
Hangzhou, China



Prof. Xie is the Vice-president of Chinese Urological Association, President of Zhejiang Urological Association, President of the Committee of Genitourinary Tumor of Zhejiang Anti-Cancer Association, National Representative and Scientific Programme Council Member of SIU, Adjunct Secretary General of UAA, Member of International Member Committee of AUA and an Honorary Member of EAU. Prof. Xie has innovatively developed a series of new procedures to treat BPH, including Transurethral vapor enucleation and resection of the prostate (TVERP), Transurethral vapor enucleation of the prostate (TVEP), and Ultrasound navigated TVERP/TVEP. Prof. Xie has launched a multi-center project on artificial intelligence ultrasound of prostate (AIUSP) in early diagnosis of prostate cancer with Prof. Tillmann Loch. AIUSP targeted prostate biopsy could significantly promote detection rate of prostate cancer.

Scribes:

<p>Blanca Trujillo Alba University College London</p>	 A portrait of Blanca Trujillo Alba, a woman with long blonde hair, wearing a blue sweater, smiling.	<p>Dr Blanca Trujillo Alba is a clinical research fellow at UCL. She was awarded an Accelerator Award CRUK fellowship to pursue her PhD in the Treatment Resistance team led by Prof. Attard starting in January 2020. Dr. Trujillo has a great interest in the development of liquid biopsy in prostate cancer and is currently working on Intense Plasma Sampling (IPS) to characterise drug resistance and clonal dynamics in metastatic prostate cancer. Blanca completed her medical degree (MBBS) in 2012 in the University “Autónoma of Madrid” and her training as a Medical Oncologist in at the “Hospital Virgen de la Salud of Toledo” in 2018. Blanca joined Prof. Attard team at UCL in September 2018 after being awarded a 2-year translational research fellowship from the “Alfonso Martín Escudero Foundation”. To date, Blanca has been a sub-investigator for a number of national and international prostate cancer trials and has joined the PRIME team: an international collaborative project whose aim is to develop a clinically implementable test which will maximize the utility of liquid biopsy by integrating genomic and transcriptomic changes and methylome status.</p>
<p>Syed Adnan Ali Clinical Research Fellow</p> <p>University of Manchester, UK</p>	 A portrait of Syed Adnan Ali, a man with dark hair and glasses, wearing a dark suit, white shirt, and maroon tie, smiling.	<p>Adnan Ali, MBBS is a clinical research fellow at the University of Manchester. He is currently evaluating the prognostic and predictive relevance of imaging based biomarkers as part of the STAMPEDE trial’s bone and imaging group.</p>

<p>Emily Grist University College London</p>		<p>Dr Emily Grist was awarded a CRUK clinical research fellowship and is completing her PhD in the Treatment Resistance team led by Prof. Attard. Dr. Grist established processes to molecularly analyse clinical samples from STAMPEDE trial participants and her work currently is focused on identifying novel molecular biomarkers to better stratify advanced prostate cancer patients, working closely with the Medical Research Council Clinical Trials Unit. Emily completed her medical degree (MBBS) in 2009 and a Biomedical BSc (Hons) in 2008 at the University of Southampton. She was an NIHR funded academic research fellow at Southampton University Hospital NHS Foundation Trust. In 2013, Emily was awarded a further NIHR academic research fellowship and commenced training in medical oncology at the Royal Marsden NHS Foundation Trust. She has been a sub-investigator for a number of national and international prostate cancer trials and is a named co-investigator on a number of grants from PCUK, PCRC, and NIH to continue working on the identification of molecular biomarkers. Emily has a keen interest in patient and public engagement, speaking at both the Pint of Science Festival and a British Science Association event.</p>
<p>Áine Haran Clinical Research Fellow</p> <p>The Christie and Salford Royal Hospital, Manchester, UK</p>		<p>Áine Haran, BSc (Hons), BMBS, MRCS, is a clinical research fellow at the Christie and Salford Royal Hospitals in Manchester, UK. She is a member of the Genito-Urinary Cancer Research Group within the Division of Cancer Sciences at the University of Manchester and an honorary research assistant at the Institute of Clinical Trials and Methodology, University College London. She is currently completing a PhD under the supervision of Professor Noel Clarke. Her research focuses on the disease burden of high-risk and metastatic prostate cancer and the use of imaging to aid risk stratification and establish prognostic and predictive biomarkers to guide management using the STAMPEDE trial imaging data. She has completed a detailed analysis of the metastatic disease burden from the “docetaxel comparison” and has demonstrated that increased nodal burden is an independent poor prognosticator associated with worse outcomes. Early results have been presented at the AUA 2020 conference.</p>

<p>Archie Macnair University College London, UK</p>		<p>Dr Macnair graduated from Newcastle Medical School with Merit before continuing his medical training in London. He is a fellow of the Royal College of Radiologists and is currently a specialist registrar in clinical oncology based primarily at the Royal Marsden Hospital. During his training he has been a National Medical Director's clinical fellow with the Faculty of Medical Leadership and Management. He is currently taking time out of training to complete a MDRes at UCL while working as a clinical research fellow on national prostate trials including the STAMPEDE and PATCH trials. His current research is investigating the feasibility of improving efficiency in oncology clinical trials using routine electronic health records.</p>
<p>Larissa Mendes University College London</p>		<p>Dr Larissa Mendes is a clinician from Brazil with training in Anatomic Pathology. She is a Clinical Research Fellow/ PhD student in the Treatment Resistance team led by Prof. Attard. Dr Mendes is currently developing the workflow for histopathological assessment of tissue samples from patients enrolled in the STAMPEDE trial. Her research focuses on how to use morphological, immunophenotypical and molecular data to accelerate the introduction of rational biomarker treatment pairings for precision treatment of men with advanced hormone-sensitive prostate cancer. She is keen on further developing the role of digital image analysis in her research as, in this new millennium, the diagnostic task will most certainly include data beyond traditional histological features and compromised surgical margins.</p> <p>The diagnosis of neoplastic diseases has been a major part of her routine as a Pathologist. There is not, in her opinion, a more important and consequential aspect of a pathologist's job than to provide the best and most thorough diagnosis to effectively guide patient care. Physicians, and an increasingly well-informed patient population, will want to know how the molecular underpinnings of tumours can impact choice of and responses to treatments. This commission represents a unique opportunity to optimise current policies and guidelines in the field of prostate cancer carefully tailoring these to specific needs of different populations.</p>

Charles Parker
University College
London



Dr Charles Parker is a Clinical Research Training Fellow who joined the Attard group in October 2020 on a 1 year Pathological Society/Jean Shanks Foundation predoctoral research bursary.

Charles completed his medical degree in 2013 at Gonville & Caius College, University of Cambridge with an intercalated BA (Hons) in Clinical Pathology and a distinction in the Final MB pathology examination. He initially completed the Academic Foundation programme in Cambridge, followed by Core Surgical Training in London, before starting Histopathology training in Edinburgh where he received a Distinction in the Postgraduate Certificate in Molecular Pathology and Genomic Medicine from the University of Edinburgh.

Charles is interested in how digital analysis of histological features can be harnessed to improve the prognostic information yield from patient biopsies, and how morphological assessment can be integrated with genomic data and other molecular techniques.

Hannah Rush
University College
London



Dr Hannah Rush is a clinical research fellow at the Medical Research Council Clinical Trials Unit working on the STAMPEDE trial.

Hannah completed her medical degree (MbChB Hons) at the University of Liverpool with an intercalated BSc in Psychology from Kings College London. She has completed MRCP and the SCE in medical oncology.

She worked as a medical registrar in oncology in Auckland Hospital, New Zealand before returning to the UK to complete her speciality training in medical oncology in South London Deanery. Her training to date includes experience working in early phase trials at Guys Hospital and she has been a sub-investigator on many national and international phase 1-3 clinical trials.

She is currently taking time out of programme to complete an MD(Res) at UCL. Her research is focussed on exploring factors that influence choice of upfront treatment in advanced and metastatic prostate cancer. In particular she has been looking at quality of life data from participants in the STAMPEDE trial, with early results from this presented at GU-ASCO this year.

<p>Naomi Lee Senior executive editor of The Lancet, London, UK</p>	 A professional headshot of Naomi Lee, a woman with long brown hair, wearing a dark grey blazer over a black top, set against a plain light grey background.	<p>Naomi Lee is a Senior Executive Editor at <i>The Lancet</i>. She heads the research section of the journal, leading the development and implementation of the research strategy for <i>The Lancet</i>, and advising on the research content of the other journals in the <i>Lancet</i> family of journals. Naomi handles peer review and commissioning across a broad range of subjects including her specialist areas of surgery, oncology, digital medicine/AI/medical technology. She is also a vice chair for the ITU/WHO Focus Group on Artificial Intelligence for Health.</p>
<p>Pip Wilkinson The Institute of Cancer Research, London</p>	 A professional headshot of Pip Wilkinson, a woman with dark hair pulled back, wearing a black top, set against a plain light grey background.	<p>Commission secretary</p>